中文摘要：

目的观察初诊2型糖尿病周围神经病变患者应用前列地尔、α-硫辛酸及甲钴胺的临床疗效。方法选取初诊2型糖尿病周围神经病变患者350例,随机分为前列地尔＋α-硫辛酸＋甲钴胺组71例,前列地尔＋α-硫辛酸组69例,α-硫辛酸＋甲钴胺组72例,前列地尔＋甲钴胺组68例,对照组70例,比较5组患者治疗前后的神经传导速度及临床感觉症状和总体疗效。结果 4个治疗组患者的神经传导速度及临床感觉症状均较治疗前有显著改善（P〈0.01）;与对照组相比,4个治疗组的改善程度显著优于对照组,组间差异有统计学意义（P〈0.01）,尤以前列地尔＋α-硫辛酸＋甲钴胺组改善最显著。结论在控制血糖基础上应用前列地尔、α-硫辛酸、甲钴胺的综合治疗才是治疗和改善糖尿病周围神经病变的关键。

英文摘要：

Objective To observe the clinical efficacy of prostaglandin E1, alpha lipoic acid and mecobalamin on first diagnosis of type 2 diabetes peripheral neuropathy. Methods 350 patients with first diagnosis of type 2 diabetes peripheral neuropathy were selected and randomly divided into the prostaglandin E1＋alpha lipoic acid＋mecobalamin group 71 cases;prostaglandin E1＋alpha lipoic acid group 69 cases; alpha lipoic acid＋mecobalamin group 72 cases; prostaglandin E1＋mecobalamin group 68 cases; control group 70 cases. The nerve conduction velocity , sensory symptoms and overall clinical efficacy were compared before and after treatment among the 5 groups. Results The nerve conduction velocity and the clinical symptoms of feeling in the 4 treatment groups improved compared with before treatment （ P 〈 0. 01 ）; compared with the control group, the 4 treatment groups improved significantly better, the difference between groups was statistically significant （ P 〈 0. 01 ） , and the prostaglandin E1＋alpha lipoic acid＋mecobalamin group improved the most significantly. Conclusion On the basis of blood sugar control, comprehensive therapy of prostaglandin E1, alpha lipoic acid and mecobalamin is the key in treating and improving diabetic peripheral neuropathy.